Du Y, Shi R, Zhang Y, Duan X, Li L, Zhang J, Wang F, Zhang R, Shen H, Wang Y, Wu Z, Peng Q, Pan T, Sun W, Huang W, Feng Y, Feng H, Xiao J, Tan W, Wang Y, Wang C, Yan J. A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants. Nat Commun. 2021 Aug 17;12(1):5000. doi: 10.1038/s41467-021-25331-x. PMID: 34404805; PMCID: PMC8371079.

Du Y, Shi R, Zhang Y, Duan X, Li L, Zhang J, Wang F, Zhang R, Shen H, Wang Y, Wu Z, Peng Q, Pan T, Sun W, Huang W, Feng Y, Feng H, Xiao J, Tan W, Wang Y, Wang C, Yan J. A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants. Nat Commun. 2021 Aug 17;12(1):5000. doi: 10.1038/s41467-021-25331-x. PMID: 34404805; PMCID: PMC8371079.

Zhang Q, Ju B, Ge J, Chan JF, Cheng L, Wang R, Huang W, Fang M, Chen P, Zhou B, Song S, Shan S, Yan B, Zhang S, Ge X, Yu J, Zhao J, Wang H, Liu L, Lv Q, Fu L, Shi X, Yuen KY, Liu L, Wang Y, Chen Z, Zhang L, Wang X, Zhang Z. Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2. Nat Commun. 2021 Jul 9;12(1):4210. doi: 10.1038/s41467-021-24514-w. PMID: 34244522; PMCID: PMC8270942.

Cao Y, Yisimayi A, Bai Y, Huang W, Li X, Zhang Z, Yuan T, An R, Wang J, Xiao T, Du S, Ma W, Song L, Li Y, Li X, Song W, Wu J, Liu S, Li X, Zhang Y, Su B, Guo X, Wei Y, Gao C, Zhang N, Zhang Y, Dou Y, Xu X, Shi R, Lu B, Jin R, Ma Y, Qin C, Wang Y, Feng Y, Xiao J, Xie XS. Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines. Cell Res. 2021 Jul;31(7):732-741. doi: 10.1038/s41422-021-00514-9. Epub 2021 May 21. PMID: 34021265; PMCID: PMC8138844.

Wu J, Zhang L, Zhang Y, Wang H, Ding R, Nie J, Li Q, Liu S, Yu Y, Yang X, Duan K, Qu X, Wang Y, Huang W. The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom. Front Immunol. 2021 Jun 17;12:687869. doi: 10.3389/fimmu.2021.687869. PMID: 34220844; PMCID: PMC8247764.

Zhang L, Li Q, Nie J, Ding R, Wang H, Wu J, Li X, Yang X, Huang W, Wang Y. Cellular tropism and antigenicity of mink-derived SARS-CoV-2 variants. Signal Transduct Target Ther. 2021 May 17;6(1):196. doi: 10.1038/s41392-021-00617-0. PMID: 34001855; PMCID: PMC8127491.

Li Q, Nie J, Wu J, Zhang L, Ding R, Wang H, Zhang Y, Li T, Liu S, Zhang M, Zhao C, Liu H, Nie L, Qin H, Wang M, Lu Q, Li X, Liu J, Liang H, Shi Y, Shen Y, Xie L, Zhang L, Qu X, Xu W, Huang W, Wang Y. SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. Cell. 2021 Apr 29;184(9):2362-2371.e9. doi: 10.1016/j.cell.2021.02.042. Epub 2021 Feb 23. PMID: 33735608; PMCID: PMC7901273.

Nie J, Li Q, Zhang L, Cao Y, Zhang Y, Li T, Wu J, Liu S, Zhang M, Zhao C, Liu H, Nie L, Qin H, Wang M, Lu Q, Li X, Liu J, Liang H, Jiang T, Duan K, Yang X, Shen Y, Huang W, Wang Y. Functional comparison of SARS-CoV-2 with closely related pangolin and bat coronaviruses. Cell Discov. 2021 Apr 6;7(1):21. doi: 10.1038/s41421-021-00256-3. PMID: 33824288; PMCID: PMC8022302.

Zhao MM, Yang WL, Yang FY, Zhang L, Huang WJ, Hou W, Fan CF, Jin RH, Feng YM, Wang YC, Yang JK. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. Signal Transduct Target Ther. 2021 Mar 27;6(1):134. doi: 10.1038/s41392-021-00558-8. PMID: 33774649; PMCID: PMC7997800.

Zhu L, Deng YQ, Zhang RR, Cui Z, Sun CY, Fan CF, Xing X, Huang W, Chen Q, Zhang NN, Ye Q, Cao TS, Wang N, Wang L, Cao L, Wang H, Kong D, Ma J, Luo C, Zhang Y, Nie J, Sun Y, Lv Z, Shaw N, Li Q, Li XF, Hu J, Xie L, Rao Z, Wang Y, Wang X, Qin CF. Double lock of a potent human therapeutic monoclonal antibody against SARS-CoV-2. Natl Sci Rev. 2020 Dec 18;8(3):nwaa297. doi: 10.1093/nsr/nwaa297. PMID: 34676096; PMCID: PMC7798916.